| Primary |
| Metastases To Meninges |
25.7% |
| Central Nervous System Lymphoma |
12.3% |
| Non-hodgkin's Lymphoma |
8.6% |
| Product Used For Unknown Indication |
7.8% |
| Acute Lymphocytic Leukaemia |
7.3% |
| Lymphoma |
7.1% |
| Prophylaxis |
7.1% |
| Diffuse Large B-cell Lymphoma |
4.0% |
| Chronic Lymphocytic Leukaemia |
3.3% |
| Leukaemia |
2.0% |
| Acute Lymphocytic Leukaemia Recurrent |
1.8% |
| Acute Myeloid Leukaemia |
1.8% |
| Central Nervous System Leukaemia |
1.8% |
| Leukaemic Infiltration Brain |
1.5% |
| Meningeal Disorder |
1.5% |
| Myeloid Leukaemia |
1.5% |
| Prophylactic Chemotherapy |
1.5% |
| Metastases To Central Nervous System |
1.3% |
| Nervous System Disorder |
1.3% |
| Acute Leukaemia |
1.0% |
|
| Vomiting |
15.8% |
| Urinary Incontinence |
13.5% |
| Neurotoxicity |
9.8% |
| Pyrexia |
7.5% |
| Cauda Equina Syndrome |
6.8% |
| Papilloedema |
5.3% |
| Urinary Retention |
4.5% |
| Vision Blurred |
4.5% |
| Vith Nerve Paralysis |
4.5% |
| Intracranial Pressure Increased |
3.0% |
| Somnolence |
3.0% |
| Thrombocytopenia |
3.0% |
| Vertigo |
3.0% |
| Arachnoiditis |
2.3% |
| Conus Medullaris Syndrome |
2.3% |
| Drug Toxicity |
2.3% |
| Headache |
2.3% |
| Leukoencephalopathy |
2.3% |
| Pain In Extremity |
2.3% |
| Polyneuropathy |
2.3% |
|
| Secondary |
| Non-hodgkin's Lymphoma |
35.7% |
| Acute Lymphocytic Leukaemia |
21.4% |
| Burkitt's Lymphoma |
14.6% |
| B Precursor Type Acute Leukaemia |
4.2% |
| Chronic Lymphocytic Leukaemia |
4.2% |
| B-cell Type Acute Leukaemia |
3.2% |
| Metastases To Meninges |
2.9% |
| Medulloblastoma |
1.9% |
| Medulloblastoma Recurrent |
1.6% |
| Non-hodgkin's Lymphoma Recurrent |
1.6% |
| Central Nervous System Lymphoma |
1.3% |
| Acute Myeloid Leukaemia Recurrent |
1.0% |
| Chronic Myeloid Leukaemia |
1.0% |
| Ischaemic Stroke |
1.0% |
| Leukaemia |
1.0% |
| Prophylaxis |
1.0% |
| Acute Myeloid Leukaemia |
0.6% |
| Aspergillosis |
0.6% |
| Product Used For Unknown Indication |
0.6% |
| Acute Leukaemia |
0.3% |
|
| Urinary Incontinence |
13.2% |
| Sigmoiditis |
10.5% |
| Candidiasis |
7.9% |
| Neurotoxicity |
7.9% |
| Epilepsy |
5.3% |
| Gastrointestinal Haemorrhage |
5.3% |
| Herpes Simplex |
5.3% |
| Pancytopenia |
5.3% |
| Pneumonia Cytomegaloviral |
5.3% |
| Renal Failure |
5.3% |
| Visual Acuity Reduced |
5.3% |
| Ataxia |
2.6% |
| Back Pain |
2.6% |
| Coordination Abnormal |
2.6% |
| Death |
2.6% |
| Encephalopathy |
2.6% |
| Fall |
2.6% |
| Fatigue |
2.6% |
| Febrile Bone Marrow Aplasia |
2.6% |
| Gait Disturbance |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
37.5% |
| B-cell Lymphoma |
15.0% |
| Multiple Myeloma |
12.5% |
| Chronic Lymphocytic Leukaemia |
10.0% |
| Myeloid Leukaemia |
10.0% |
| Diffuse Large B-cell Lymphoma |
7.5% |
| Prophylaxis |
5.0% |
| Arthralgia |
2.5% |
|
| Ataxia |
20.0% |
| Nodal Arrhythmia |
20.0% |
| Arthralgia |
10.0% |
| Diarrhoea |
10.0% |
| Haematoma |
10.0% |
| Lung Disorder |
10.0% |
| Paraesthesia |
10.0% |
| Plasmablastic Lymphoma |
10.0% |
|
